Kamada (KMDA), Kedrion Submit BLA to FDA for Human Rabies Immunoglobulin as Post-Exposure Treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall St drops as Meta Platforms, economic data weigh
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Dollar firmer on higher U.S. inflation; yen sinks vs euro, US currency
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
September 1, 2016 6:30 AM EDTKamada and Kedrion, collaborators on development and commercialization of post-exposure treatment for suspected rabies, announced today the filing of a BLA with the FDAOn approval by FDA, the product will represent a new option in a market where supply of post-exposure rabies treatment has been inconsistent over timeCompanies planning for decision from FDA in mid-2017
NESS ZIONA, Israel and FORT LEE, N.J., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA)Â (TASE: KMDA), a plasma-derived... More
Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment
September 1, 2016 6:29 AM EDTKamada and Kedrion, collaborators on development and commercialization of post-exposure treatment for suspected rabies, announced today the filing of a BLA with the FDA. On approval by FDA, the product will represent a new option in a market where supply of post-exposure rabies treatment has been inconsistent over time. Companies planning for decision from FDA in mid-2017.
NESS ZIONA, Israel & FORT LEE, N.J.--(BUSINESS WIRE)-- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived... More
